PTC Therapeutics vs Royalty Pharma
Royalty Pharma reported revenue of $2.4 billion in fiscal 2025, 1.4 times PTC Therapeutics' $1.7 billion in fiscal 2025. PTC Therapeutics' revenue grew 114.5% in its latest year, and Royalty Pharma's grew 5.1%. PTC Therapeutics had an operating margin of 50.1%, against 65.6% at Royalty Pharma.
Side by side
| PTC Therapeutics | Royalty Pharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.7B | $2.4B |
| Revenue growth | 114.5% | 5.1% |
| Revenue growth a year, last 5 years | 35.4% | 2.3% |
| Gross margin | — | — |
| Operating margin | 50.1% | 65.6% |
| Net margin | 39.4% | 32.4% |
| Free cash flow | $702M | — |
| Free cash flow margin | 40.6% | — |
| Return on capital | — | 8.9% |
| Net debt to EBITDA | — | 5.3x |
| Dividends and buybacks | $0M | $1.2B |
| Change in diluted share count | 14.9% | −5.0% |
| Last close | $58.33 | $67.72 |
| P/E at the last close | — | 44.3× |
| Insider trades, last 12 months | sold $55.0 million | sold $110.9 million |
| Piotroski F-score | — | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
PTC TherapeuticsRoyalty Pharma
Operating margin
Percent of revenue
PTC TherapeuticsRoyalty Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PTC TherapeuticsRoyalty Pharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the PTC Therapeutics and Royalty Pharma pages.